

**International Conference**  
**“CLINICAL GENETICS OF CANCER 2024”**  
**Szczecin, 26<sup>th</sup>-27<sup>th</sup> September 2024**  
**(Pomeranian Medical University in Szczecin, Rybacka 1)**


**Organisers / organizatorzy:**

**Department of Genetics and Pathology, Pomeranian Medical  
University in Szczecin**

**Zakład Genetyki i Patomorfologii Pomorskiego Uniwersytetu  
Medycznego w Szczecinie**

**International Hereditary Cancer Center of Pomeranian Medical University  
in Szczecin**

**Międzynarodowe Centrum Nowotworów Dziedzicznych Pomorskiego  
Uniwersytetu Medycznego w Szczecinie**



**Section of Clinical Genetics of Cancer of Polish Society of Human Genetics**  
**Sekcja Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki  
Człowieka**

**Honorary patronage / Honorowy patronat:**

**Marshal of the Zachodniopomorskie Voivodeship /  
Marszałka Województwa Zachodniopomorskiego, Olgierda Geblewicza**



PATRONAT HONOROWY  
MARSZAŁKA WOJEWÓDZTWA  
ZACHODNIOPOMORSKIEGO  
OLGIERDA GEBLEWICZA

**President of the City of Szczecin /  
Prezydenta Miasta Szczecin, Piotra Krzystka**



Patronat Honorowy  
Prezydenta  
Miasta Szczecin

**Rector of Pomeranian Medical University in Szczecin /  
J.M. Rektor PUM, prof. dr hab. n. med. Leszek Domański**



PATRONAT HONOROWY REKTORA  
POMORSKIEGO UNIWERSYTETU  
MEDYCZNEGO W SZCZECINIE

**Regional Medical Chamber in Szczecin  
Okręgowa Izba Lekarska w Szczecinie**



## Sponsors / Sponsorzy:



Marszałek Województwa  
Zachodniopomorskiego



Szczecin



## Thursday - 26<sup>th</sup> September 2024

<b>8:45 - 9:00</b>	<b>Conference opening</b>
9:00 - 9:30	Tumour Mutational Burden using the TSO-500: How does it help in patient management (R. Scott, Newcastle)
9:30 - 10:00	Germline genetic of rare cancers (K. Hemminki, Pilsen, Heidelberg)
10:00 - 10:30	Germline variants in cancer patients with personal and family history of colorectal cancer: an update (A. Försti, Heidelberg)
10:30 - 11:00	Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated “Big Bang” pathway to CRC in three of the four Lynch syndromes. (P. Moller, Oslo) on-line
<b>11:00 - 11:30</b>	<b>Coffee break</b>
11:30 - 11:40	Association between Blood Levels of Selenium, Zinc and Copper and Survival in Colorectal Cancer Patients with Lynch Syndrome (M. Marciniak, Szczecin)
11:40 - 11:55	Spectrum of the mutations predisposing to occurrence of colorectal polyposis (A. Pławski, Poznań)
11:55 - 12:25	Treatment of BRCA1-positive ER+ breast cancer: An observational study (S. Narod, Toronto)
12:25 - 12:55	Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: lower rates for 5-years post chemotherapy (G. Evans, Manchester)
12:55 - 13:15	Bilateral oophorectomy and all-cause mortality in women with <i>BRCA1</i> and <i>BRCA2</i> mutations (J. Kotsopoulos, Toronto)
13:15 - 13:35	Ovarian cancer prevention in the general and in the high risk population (R. Fruscio, Milan)
13:35 - 13:55	Polygenic inheritance and the risk of ovarian carcinoma (E. Grzybowska, Gliwice)
13:55 - 14:15	Bilateral Mastectomy and Breast Cancer Mortality (V. Giannakeas, Toronto)
<b>14:15 - 15:00</b>	<b>Lunch</b>
15:00 - 15:20	Prostate cancer genetics in practice now and in the future (J. McHugh, London) on-line
15:20 - 15:35	Personalized nanodiagnosics of prostate cancer. A proposal for repositioning genetic testing on the timeline of the diagnostic and therapeutic process (B. Kałużewski, Łódź)
15:35 - 15:45	Serum Copper, Zinc, and Copper/Zinc Ratio Levels as Biomarkers of Survival Among Prostate Cancer Patients (S. Pietrzak, Szczecin)
15:45 - 16:00	MRI Surveillance and Breast Cancer Mortality in Women with BRCA1 and BRCA2 Sequence Variations (J. Gronwald, Szczecin)

16:00 - 16:15	Pilot results of elements blood levels of computational analyses in diagnosis of cancer risk among BRCA1 carriers (Z. Suszyński, Koszalin)
16:15 - 16:25	Blood Elements Levels and Cancer Risk in BRCA1 Mutation Carriers: A Prospective Study (M. Matuszczak, Szczecin)
16:25 - 16:35	Blood cells of <i>BRCA1</i> mutation and epimutation carriers appear to acquire specific epigenetic signatures (K. Sokołowska, Szczecin)
16:35 - 16:45	Blood and urinary arsenic levels are associated with methylation of promoters of genes involved in molecular processes related to arsenic toxicity. (K. Sokołowska, Szczecin)
<b>16:45 - 17:15</b>	<b>Coffee break</b>
17:15 - 17:35	BRCA1/2 population screening pilot in Latvia. Lessons to learn (A. Irmejs, Riga)
17:35 - 17:50	SELINA – optimization of Se and As blood levels is decreasing cancer risk in females from families with predisposition to hereditary breast cancers (J. Lubiński, Szczecin)
17:50 - 18:05	The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (M. Szwiec, Zielona Góra)
18:05 - 18:15	Association of constitutional <i>BRCA1</i> methylation with genetic alterations in promoter region and genome-wide methylation signature (K. Prajzenc, Szczecin)
18:15 - 18:25	Results of DMSA long-term supplementation in lowering lead blood level (E. Siwiec, Szczecin)
18:25 - 18:45	Genomic instability, microenvironment and telomere homeostasis in solid malignancies (P. Vodička, Pilsen)
18:45 - 18:55	MCR1 as prognostic marker in malignant melanoma (T. Dębniak, Szczecin)
18:55 - 19:05	Methylome-based Pan Cancer Classifier (MePCC) - pan-cancer classification based on methylomics data (J. Bińkowski, Szczecin)
<b>19:05</b>	<b>Dinner</b>
<b>Friday – 27<sup>th</sup> September 2024</b>	
8:30 - 8:40	Evaluation of serum selenium concentration and polymorphisms of genes responsible for selenium metabolism in women with endometrial cancer (M. Jankowska, Rzeszów) on-line
8:40 - 8:50	Axiom_PolMut1 - polish custom genetic test for cancer predisposition and other genetically determined diseases (K. Białkowska, Szczecin)
8:50 - 9:00	Blood and Serum Se and Zn Levels and 10-Year Survival of Patients after a Diagnosis of Kidney Cancer (E. Złowocka-Perłowska, Szczecin)
9:00 - 9:10	Are current Polish guidelines for prophylactic mastectomy sufficient? (A. Stachowski, Szczecin)
9:10 - 9:25	(R. Mądry, Poznań) on-line

9:25 - 9:40	Population screening for founder mutations of high cancer risk in Poland (C. Cybulski, Szczecin)
9:40 - 9:50	PALB2 mutation female carriers registry (A. Stachowski, Szczecin)
9:50 - 10:05	Determining homologous recombination deficiency (HRD) in comprehensive genomic profiling (CGP) (A. Tysarowski, Warszawa)
10:05 - 10:20	Rozliczanie badań genetycznych w wybranych nowotworach - możliwości i bariery (A. Tysarowski, Warszawa)
<b>10:20 - 10:50</b>	<b>Coffee break</b>
10:50 - 11:20	Organizacje pacjenckie: Osobista i medyczna podróż pacjentki z mutacjami BRCA2 i CHECK2 (S. Pogorzelska - Ogólnopolskie Stowarzyszenie Wspierania Rodzin z Predyspozycjami do Nowotworów Dziedzicznych) on-line OmeaReh rehabilitacja chorych na raka piersi w warunkach domowych (A. Woźniak-Marciniak - Fundacja OmeaLife Rak piersi nie ogranicza)
11:20 - 13:00	Meeting of Section of Clinical Genetics of Cancer of Polish Society of Human Genetics National Programme of Diagnostics and Surveillance in Families with Increased Predisposition to Cancers - analysis of current arrangements - (O. Haus, Bydgoszcz) - (M. Stawicka, Zielona Góra) - (A. Prusaczyk, Siedlce)
13:00 - 13.30	Certyfikacja umiejętności z genetyki klinicznej nowotworów dla lekarzy i nie-lekarzy – doradców genetycznych (T. Dębniak, J. Lubiński, Szczecin)
<b>13:30</b>	<b>Closing</b>
	<b>Lunch</b>